Listed by the USPTO as GAUGER, PAUL RANDALL
Tech Center 1600 • Art Units: 1626 1629
This examiner grants 59% of resolved cases
GAUGER, PAUL RANDALL works in USPTO tech center 1600 and art unit 1626. The record includes 27 resolved cases, an allowance rate of 59.3%, and a median of 1276 days to allowance. The 8.3% interview lift indicates a modest positive association, so interviews may be considered selectively within a broader written-response strategy.
The listed companies are Hoffmann-La Roche Inc., Bristol-Myers Squibb Company, and Alcon Inc. The listed firms are Clark+Elbing LLP, Milstein Zhang & Wu LLC, and POLSINELLI PC (Main Customer Number). Because the record covers 27 cases, practitioners should treat the metrics as limited while using the 1276-day median for planning.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18615197 | TREATMENT OF BREAST CANCER | Non-Final OA | Individual inventor |
| 18454315 | BENZOTHIAZOLYL BICYCLO[1.1.1]PENTANE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | Non-Final OA | Hoffmann-La Roche Inc. |
| 19574713 | TRIAZOLOPYRIDINYL ETHER LINKED COMPOUNDS AS KINASE INHIBITORS | Non-Final OA | Bristol-Myers Squibb Company |
| 18558974 | PHARMACEUTICAL PREPARATION | Non-Final OA | ALCON INC. |
| 18304048 | ABBAPOLINS AS INHIBITORS AND DEGRADERS OF POLO-LIKE KINASES | Final Rejection | UNIVERSITY OF SOUTH CAROLINA |
| 17764003 | METHODS FOR TREATING HYPERPHENYLALANINEMIA | Final Rejection | PTC Therapeutics MP, Inc. |
| 18538777 | 4-SUBSTITUED CYTISINE ANALOGUES | Final Rejection | The University of Bristol |
| 17638669 | A PHARMACEUTICAL COMPOSITION FOR TREATING CANCER USED FOR A PATIENT HAVING SPECIFIC GENETIC MARKER | Final Rejection | J-PHARMA CO., LTD. |
| 18605432 | METHODS AND USES OF BORON COMPOUNDS IN THE TREATMENT OF NONTUBERCULOUS MYCOBACTERIUM INFECTIONS AND PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF SAME | Non-Final OA | MICURX PHARMECEUTICALS, INC. |
| 18605444 | PRODRUGS OF BORON COMPOUNDS AND THEIR USE IN TREATING BACTERIAL INFECTIONS | Non-Final OA | SHANGHAI MICURX PHARMACEUTICALS CO., LTD. |
| 18468510 | HAPH ANALOGS AND THERAPEUTIC AND DIAGNOSTIC USES THEREOF | Non-Final OA | Medical Research & Consulting Services, LLC |
| 18272939 | COMPOSITIONS AND METHODS FOR TREATING CANCER | Final Rejection | Yanping KONG |
| 17637372 | COMPOSITIONS AND METHODS USING NON-STEROIDAL ANTI-INFLAMMATORY DRUGS | Final Rejection | APPLIED BIOLOGICAL LABORATORIES, INC. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy59.3% of resolved applications examined by Paul Randall Gauger were allowed (27 resolved cases), compared with 54.9% across Art Unit 1626 over the last five years.
This examiner's interview lift is +8.3 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Paul Randall Gauger took 1,276 days on average from filing to allowance.
Paul Randall Gauger examines applications in Art Unit 1626 in Tech Center 1600 (Biotechnology & Pharmaceuticals).
